PATENT CLAIM ANALYSIS

Application Number: 15894741
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["424", "158100"]

Abstract:
Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.

Claim (Index 35):
The polypeptide according to  claim 28 , wherein said scFv further inhibits CD5dull B220+ and ROR1bright B220+ leukemic B cell expansion or proliferation.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.36585
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13997934', '14846400', '15346967', '15619119', '14422519']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.839125715809398
- 35 USC 102 Novelty (BERT): 0.582185881924155
- Combined Prediction Score: 0.8134317324208737
- Mean Citation Score: 532.8721939999998
- Max Citation Score: 580.2986
- Similarity Product: 385.3330941975116

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test